Last reviewed · How we verify
RP2 Monotherapy
At a glance
| Generic name | RP2 Monotherapy |
|---|---|
| Also known as | RP2 |
| Sponsor | Replimune Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (PHASE1)
- Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RP2 Monotherapy CI brief — competitive landscape report
- RP2 Monotherapy updates RSS · CI watch RSS
- Replimune Inc. portfolio CI